Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
42
EDSA Quote, Financials, Valuation and Earnings
Last price:
$2.39
Seasonality move
:
14.79%
Day range:
$2.18 - $2.40
52-week range:
$1.55 - $5.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
25.98x
P/B ratio:
2.50x
Volume:
90.1K
Avg. volume:
24.1K
1-year change:
-52.62%
Market cap:
$15.9M
Revenue:
--
EPS (TTM):
-$1.59
Analysts' Opinion
-
Consensus RatingEdesa Biotech has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.33, Edesa Biotech has an estimated upside of 357.23% from its current price of $2.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $2.26.
Fair Value
-
According to the consensus of 1 analyst, Edesa Biotech has 357.23% upside to fair value with a price target of $10.33 per share.
EDSA vs. S&P 500
-
Over the past 5 trading days, Edesa Biotech has overperformed the S&P 500 by 7.3% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Edesa Biotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Edesa Biotech revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Edesa Biotech reported revenues of --.
Earnings Growth
-
Edesa Biotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Edesa Biotech reported earnings per share of -$0.30.
Enterprise value:
11.2M
EV / Invested capital:
--
Price / LTM sales:
25.98x
EV / EBIT:
--
EV / Revenue:
33.94x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$13.4M | -$7.5M | -$5.8M | -$1.9M | -$1.6M | |
| EBITDA | -$13.3M | -$7.3M | -$5.7M | -$1.9M | -$1.6M | |
| Diluted EPS | -$5.39 | -$2.36 | -$1.59 | -$0.58 | -$0.30 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21.4M | $18M | $8.1M | $4.2M | $14.4M | |
| Total Assets | $24M | $20.4M | $10.7M | $6.5M | $16.5M | |
| Current Liabilities | $4.6M | $3.3M | $1.6M | $2.2M | $914.7K | |
| Total Liabilities | $4.7M | $3.4M | $1.7M | $2.2M | $914.7K | |
| Total Equity | $19.3M | $17M | $9M | $4.3M | $15.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12M | -$6.3M | -$5.7M | -$1.7M | -$2.4M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $3.7M | $1.7M | $16.9M | $211.7K | $14.8M | |
| Free Cash Flow | -$12M | -$6.3M | -$5.7M | -$1.7M | -$2.4M | |
EDSA
Sector
Market Cap
$15.9M
$34.4M
Price % of 52-Week High
40.43%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-52.62%
-37.36%
Beta (5-Year)
0.393
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.13
200-day SMA
Sell
Level
$2.38
Bollinger Bands (100)
Buy
Level
2 - 2.38
Chaikin Money Flow
Buy
Level
112.3K
20-day SMA
Buy
Level
$2.06
Relative Strength Index (RSI14)
Buy
Level
66.23
ADX Line
Buy
Level
22.64
Williams %R
Neutral
Level
-28.1135
50-day SMA
Buy
Level
$2.04
MACD (12, 26)
Buy
Level
0.59
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
237.5K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Stock Forecast FAQ
In the current month, EDSA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EDSA average analyst price target in the past 3 months is $10.33.
-
Where Will Edesa Biotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Edesa Biotech share price will rise to $10.33 per share over the next 12 months.
-
What Do Analysts Say About Edesa Biotech?
Analysts are divided on their view about Edesa Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Edesa Biotech is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Edesa Biotech's Price Target?
The price target for Edesa Biotech over the next 1-year time period is forecast to be $10.33 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EDSA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Edesa Biotech is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of EDSA?
You can purchase shares of Edesa Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Edesa Biotech shares.
-
What Is The Edesa Biotech Share Price Today?
Edesa Biotech was last trading at $2.39 per share. This represents the most recent stock quote for Edesa Biotech. Yesterday, Edesa Biotech closed at $2.26 per share.
-
How To Buy Edesa Biotech Stock Online?
In order to purchase Edesa Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
